Abstract
In this issue of Blood Advances, Amaya et al 1 report a phase 1/1b study of an all-oral regimen with CC-486 and venetoclax (Ven) in acute myeloid leukemia (AML), continuing the evolution of AML therapy toward all-oral regimens.The development of azacitidine plus Ven (Aza-Ven) represented a major advance for older adults and medically unfit patients with AML, a population historically associated with poor outcomes and limited treatment options.Before Ven-based therapy, patients ineligible for intensive induction chemotherapy were treated with hypomethylating agents (HMAs), low-dose cytarabine, or best supportive care.HMA monotherapy produced modest responses, and median overall survival (OS) was <1 year.These limitations highlighted the need for combinations capable of producing deep and durable remissions without the toxicity of conventional induction therapy.